DexCom, Inc. vs Schwab US Dividend Equity ETF — how do they compare? DexCom, Inc. trades at $89.53 (market cap $33.08B), while Schwab US Dividend Equity ETF trades at $34.24. Which is the better fit depends on your goals.
| DXCM | SCHD | |
|---|---|---|
Market Cap | $33.08B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $34.27 |
52-Week Low | $54.84 | $26.44 |
Enterprise Value | $32.53B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SCHD, the Schwab U.S. Dividend Equity ETF, trades at $33.90, up 0.59% today, with a bullish technical signal from moving averages and neutral oscillators. The ETF focuses on high-quality U.S. dividend-paying stocks, offering income stability. Recent news highlights its popularity among retirees for generating passive income, with institutional buying activity noted in Q2 2026 filings.
The outlook for SCHD remains positive for income-focused investors, leveraging dividend growth and low costs. Risks include interest rate sensitivity and market volatility affecting dividend stocks. Analyst sentiment is generally favorable, emphasizing its role in diversified retirement portfolios.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →SCHD is an ETF that tracks the Dow Jones U.S. Dividend 100 Index. It selects high-quality companies with a consistent track record of paying dividends, focusing on financial strength metrics like cash flow to total debt and return on equity, and excluding REITs. The fund aims to provide both income and capital appreciation, making it a popular choice for long-term, dividend-focused investors.
Read more on SCHD →